Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma

Br J Haematol. 2015 Jul;170(1):131-4. doi: 10.1111/bjh.13275. Epub 2015 Jan 6.

Authors

Michelle Furtado¹, Michael L Wang², Brian Munneke³, Jesse McGreivy³, Darrin M Beaupre³, Simon Rule⁴

Affiliations

¹ Plymouth University Schools of Medicine and Dentistry, Plymouth, Devon, UK.
² Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Pharmacyclics, Inc., Sunnyvale, CA, USA.
⁴ Plymouth University Schools of Medicine and Dentistry, Plymouth, Devon, UK. simon.rule@nhs.net.

PMID: 25559624
DOI: 10.1111/bjh.13275

No abstract available

Keywords: bone marrow; bruton tyrosine kinase inhibitor; ibrutinib; lymphocytosis; mantle cell lymphoma.

Publication types

Letter

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Bone Marrow / enzymology
Bone Marrow / metabolism
Bone Marrow / pathology*
Humans
Lymphocytosis / chemically induced
Lymphocytosis / etiology*
Lymphocytosis / pathology
Lymphoma, Mantle-Cell / drug therapy
Lymphoma, Mantle-Cell / enzymology
Lymphoma, Mantle-Cell / pathology*
Piperidines
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrazoles / administration & dosage
Pyrazoles / adverse effects*
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Adenine